IO Biotech

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

IO Biotech today reported financial results for the second quarter ended June 30, 2024. Read more: https://bit.ly/3AnOcCy #IOBiotech #cancer #financialresults 

Members of the IO Biotech management team will be heading to Barcelona, Spain for ESMO - European Society for Medical Oncology 2024 on September 13th – 17th to connect with fellow oncology professionals. Reach out to us at info@iobiotech.com to meet with our CEO Mai-Britt Zocca, CMO Dr. Qasim Iftikhar Ahmad, or CBO Faical Miyara Ph.D, to learn more about our novel investigational IO102-IO103 therapeutic cancer vaccine. We hope to see you at our poster presentation at the congress, "A phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)", presentation no. 1022P. 

Summer is the time of year when people spend more time outdoors and this Summer Sun Safety Month, IO Biotech encourages everyone to stay safe while enjoying the sun. Remember to prioritize skin health and be mindful of the risks of #melanoma, a serious form of #skincancer linked to UV exposure.   The "ABCDE" rule is helpful in remembering the warning signs of melanoma: ·       Asymmetry. The shape of one-half of the mole does not match the other ·       Border. The edges are ragged, notched, uneven, or blurred ·       Color. Shades of black, brown, and tan may be present ·       Diameter. Can be smaller than a pencil eraser ·       Evolving. Shape is changing in size, shape, or color   To learn more about IO Biotech and our T-win® immune-modulating therapeutic cancer vaccine, please visit our website: www.iobiotech.com. '#SummerSunSafety #MelanomaAwareness #IOBiotech

IO Biotech is pleased to announce that it will be presenting a poster at the ESMO - European Society for Medical Oncology Congress 2024. The poster is entitled "A phase 2 trial of the IO102-IO103 vaccine plus pembrolizumab: completed cohort for first line (1L) treatment of advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)" and will share data from one of the Phase 2 basket trials of IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The data for the complete squamous cell carcinoma of the head and neck (SCCHN) cohort of the IOB-022/KN-D38 study will be presented at the Congress, which takes place in Barcelona from September 13-17, 2024. We look forward to sharing these exciting data. See full details here: https://bit.ly/4fiB5m2 #ESMO24 #IOBiotech #cancer #SCCHN

July is UV Safety Month. Most skin cancers are caused by too much exposure to ultraviolet (UV) light. Learn more on how to protect yourself when outdoors year-round with three simple steps from the American Academy of Dermatology Association here: https://bit.ly/4bHv6Em #PracticeSafeSun

IO Biotech is proud to congratulate Inge-Marie Svane, MD, PhD, one of our co-founders, on receiving the prestigious Kirsten and Freddy Johansen’s Medical Scientific Clinical Researcher Award 2024! We want to thank Dr. Svane for all of her contributions and research efforts to help people with cancer around the world.

IO Biotech is hiring. Learn more here: https://bit.ly/4cvL8lC

Last week IO Biotech's President and CEO, Mai-Britt Zocca, PhD, and member of the board of directors of DANISH BIO - DANSK BIOTEK, expressed her views on the Government’s new Entrepreneurial Strategy on Danish TV. Read more here: https://lnkd.in/e3-NtZ7V

June is National Cancer Survivors Month, a time to celebrate and honor the resiliency and strength of the more than 18 million cancer survivors across the U.S. Learn how to support survivors: https://lnkd.in/exMcfXTy